Drug Target Review

MARCH 4, 2025

Phenomix Sciences , led by CEO Mark Bagnall, is using precision medicine to make treatments more targeted and effective. Phenomix Sciences, built on over a decade of clinical research at the Mayo Clinic, is disrupting this outdated approach. Meet Mark Bagnall Mark Bagnall currently serves as CEO of Phenomix Sciences, Inc.

Therapies 52

Therapies Treatment Clinical Trials Science 52

Drug Target Review

MARCH 17, 2025

Previously, he served as VP of Science & External Innovation at Allergan, where he played a pivotal role in the global development of zelquistinel, a third-generation oral N-methyl-D-aspartate (NMDA) receptor modulator. Meet Dr John Donello Dr John Donello serves as CSO at Gate Neurosciences.

Treatment 52

Treatment Licensing Licensing Science 52

The Pharma Data

JUNE 24, 2025

The extended agreement will support joint research efforts targeting critical therapeutic areas, including oncology, cardiovascular and renal diseases, neurology, rare diseases, and immunology. This progress is driven by the dedicated efforts and strong collaborations among innovators of science and business.

Pharma R&D 40

Pharma R&D Pharmaceutical Companies Pharmaceuticals Science 40

The Pharma Data

JULY 18, 2021

Food and Drug Administration (FDA) granted Priority Review designation for the Biologics License Application (BLA) for their mRNA vaccine to prevent COVID-19 in individuals 16 years of age and older. The Pfizer-BioNTech COVID-19 vaccine has not been approved or licensed by the U.S. Pfizer Inc. About BioNTech.

Licensing 52

Licensing Licensing Vaccine FDA 52

The Pharma Data

NOVEMBER 17, 2020

Lead Pharma has entered into a collaboration and license agreement with Roche , hoping to lead the way in the development of oral small molecules for immune-mediated diseases like rheumatoid arthritis, psoriasis and inflammatory bowel diseases. . The agreement encompasses Lead Pharma’s entire pipeline.

Small Molecule 52

Small Molecule Disease Immune Response Licensing 52

The Pharma Data

JANUARY 31, 2021

–( BUSINESS WIRE )– Gilead Sciences, Inc. While HIV treatment has advanced dramatically over the past three decades, people living with HIV still face a lifetime of therapy,” said Diana Brainard, MD, Senior Vice President, Virology Therapeutic Area, Gilead Sciences. Nasdaq: GILD) and Gritstone Oncology, Inc.

Vaccine 52

Vaccine Science Clinical Trials Licensing 52

Drug Target Review

OCTOBER 14, 2024

His current role at Mironid focuses on developing treatments for rare genetic kidney diseases, and his insights reveal the challenges and potential of integrating advanced technologies like artificial intelligence (AI) into the drug discovery process. Raminderpal is currently the Global Head of AI and GenAI Practice at 20/15 Visioneers.

Science 52

Science Pharmaceutical Companies Drug Development Pharmaceuticals 52

The Pharma Data

JUNE 7, 2022

AL01811 is a preclinical selective GBA2 inhibitor with first-in-class potential as an oral disease modifying treatment for Parkinson’s Disease Alectos to receive a $15 million upfront payment and is eligible to receive potential future development and commercial milestone payments. Biogen Inc. President and CEO at Alectos Therapeutics.

Licensing 40

Licensing Licensing Small Molecule Disease 40

Drug Target Review

APRIL 14, 2025

A deep interest in political science and the political economy of drugs led him to focus on how drugs are priced and distributed across different jurisdictions. As CEO, he oversees everything except the science, which is driven by his co-founder, Jim Roberts. Finrows role at Lumen Bioscience reflects his diverse expertise.

Therapies 52

Therapies Marketing Drug Development Treatment 52

BioPharma Drive: Drug Pricing

JUNE 23, 2025

Expanding potential uses Emerging research suggests GLP-1 drugs might effectively treat chronic kidney disease, liver conditions, and certain cardiac diseases. Additionally, preserving lean muscle mass during weight loss is a key area of focus to improve patient outcomes.

Treatment 130

Treatment Drugs Therapies FDA 130

Drug Target Review

AUGUST 9, 2024

The science behind drug formulation The formulation of a drug is both an art and a science, requiring a deep understanding of the drug’s chemical and physical properties. Inhalers are useful in respiratory conditions, whereas topical treatments can be applied directly to the skin for localised treatment.

Science 59

Science Drugs Compliance Drug Development 59

The Pharma Data

JUNE 6, 2025

Proteinuria reduction is a well-established surrogate marker for the progression of kidney disease, and this level of decline is considered both statistically significant and clinically meaningful in slowing disease progression toward end-stage kidney disease (ESKD). in the group treated with sibeprenlimab relative to placebo.

Trials 40

Trials Treatment Therapies FDA 40

Drug Target Review

SEPTEMBER 19, 2024

Based on Nobel Prize-winning research, IRLAB has grown rapidly to become recognised and respected as a world-leader in understanding the complex neuropharmacology of CNS disorders, especially Parkinson’s disease (PD). The treatment often initially provides good symptom relief and those affected by the disease can live a largely normal life.

Disease 52

Disease Drugs Treatment Drug Development 52

Drug Hunter

APRIL 20, 2023

. #2: MRTX1133 (Mirati Therapeutics/Array BioPharma, 21%) The 2nd place runner-up is MRTX1133 , the non-covalent KRAS(G12D) inhibitor and is the first reported inhibitor specific for G12D, which makes up as much as 33% of all KRAS mutations and carries a 2 to 3-fold higher disease burden than G12C.

Small Molecule 130

Small Molecule Clinical Trials Trials Licensing 130

The Pharma Data

MARCH 22, 2021

Basel, 22 March 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the decision to discontinue dosing in the Phase III GENERATION HD1 study of tominersen in manifest Huntington’s disease (HD). In December 2017, Roche licensed the investigational molecule from Ionis Pharmaceuticals. About Huntington’s disease.

Disease 52

Disease Clinical Trials Pharmacokinetics Treatment 52

The Pharma Data

DECEMBER 15, 2020

A healthy immune system defends the body against disease and other conditions. Autoimmune disease impacts different parts of the body, weakening functionality. Researchers are aware of more than 80 diseases that occur when the immune system attacks the body’s own organs, tissues and cells. It may be life-threatening.

Disease 52

Disease Clinical Trials Small Molecule Trials 52

The Pharma Data

MAY 7, 2021

The Pfizer-BioNTech COVID-19 Vaccine has not been approved or licensed by the U.S. Food and Drug Administration (FDA), but has been authorized for emergency use by FDA under an Emergency Use Authorization (EUA) to prevent Coronavirus Disease 2019 (COVID-19) for use in individuals 16 years of age and older. AUTHORIZED USE IN THE U.S.:

Licensing 52

Licensing Licensing Vaccine FDA Approval 52

The Pharma Data

DECEMBER 20, 2020

Allecra, subject to the satisfaction of terms and conditions as set forth in the Exclusive Licensing Agreement, is to receive an upfront cash payment and is eligible to receive additional development and commercial milestone payments with an overall deal value of $78 million, in addition to royalties.

Licensing 40

Licensing Licensing Pharmaceuticals Pharmaceutical Companies 40

The Pharma Data

OCTOBER 27, 2020

VANCOUVER, BC / ACCESSWIRE / October 28, 2020 / (CSE:OVAT) – Ovation Science Inc. (“Ovation” or the “Company”) is pleased to announce that its DermSafe® Hand Sanitizer Lotion is listed on Amazon.ca. DermSafe is a pharmaceutical-grade hand sanitizer lotion made without alcohol and backed by science.

Science 52

Science Production Pharmaceuticals Licensing 52

Drug Target Review

NOVEMBER 25, 2024

I started my career with a degree in biomedical sciences from the University of East Anglia in Norwich, UK. Personally, I went from working in licensing and business development in big pharma straight to being a CEO. Can you tell us about your journey in the field of STEM and the challenges you encountered along the way?

Treatment 52

Treatment Small Molecule Clinical Trials Trials 52

The Pharma Data

AUGUST 17, 2020

We are confident that the talent, experience and commitment to science-driven innovation of the Bristol Myers Squibb team will enable DF6002 to discover novel, lifesaving solutions for patients.”. About DF6002. About Bristol Myers Squibb. About Dragonfly. Dragonfly has a deep pipeline of wholly owned programs developed using its platform.

Licensing 52

Licensing Licensing Production Clinical Trials 52

Drug Target Review

JUNE 3, 2024

How does COUR Pharmaceuticals’ immune-modifying nanoparticle platform differ from traditional approaches to treating immune-mediated diseases? Essentially, our CNPs reprogramme the immune system by restoring balance and returning the body to a homeostatic state, offering a precise approach to treating immune-mediated diseases.

Disease 49

Disease Therapies Pharmaceuticals Clinical Trials 49

LifeSciVC

JULY 6, 2023

More than a decade ago, our co-founder, Dr. Greg Hurlbut, formerly the head of protein conformational and rare pulmonary diseases research at Sanofi Genzyme, developed a novel strategy to discover small molecules that directly address the key driver of molecular pathology of F508del, the most common cystic fibrosis-causing mutation.

Small Molecule 58

Small Molecule Licensing Licensing Science 58

The Pharma Data

DECEMBER 20, 2020

Interventional treatment for mitral regurgitation is considered to be one of the most challenging areas in the field of structural heart disease, yet also represents huge market potential. The terms also allow cross-licensing on future improvements of the products, encouraging both companies to focus on innovations. .”

Licensing 40

Licensing Licensing Production Treatment 40

The Pharma Data

MAY 2, 2022

– Gilead to License Exclusive Worldwide Rights to the Investigational Candidate DF7001, a 5T4-Targeting NK Cell Engager for Solid Tumors –. – Gilead to Have Options to License Several Additional NK Cell Engager Programs –. Gilead Sciences, Inc. About Gilead Sciences. Gilead Sciences, Inc.

Licensing 52

Licensing Licensing Research Protein Expression 52

Drug Target Review

FEBRUARY 1, 2024

What challenges has the industry faced in developing and commercialising treatments for neurological diseases, including rare diseases? There are a lot of drug development challenges that are, in some cases, unique to neuroscience, including neurological diseases, psychiatric disorders, and rare diseases affecting the nervous system.

Therapies 104

Therapies Drug Development Disease Clinical Development 104

The Pharma Data

DECEMBER 14, 2020

15, 2020 (GLOBE NEWSWIRE) — Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”) today announced that it entered into an exclusive licensing agreement with Oncocyte Corporation (NYSE American: OCX) to bring DetermaRx , a risk stratification test for early stage lung cancer patients, to China. About Burning Rock.

Licensing 52

Licensing Licensing Pharmaceutical Companies Treatment 52

The Pharma Data

JANUARY 5, 2021

RAD011 is a pivotal-trial ready synthetic cannabidiol oral solution with potential utilization in multiple endocrine and metabolic orphan diseases. We intend to use PWS as the anchor indication and will further investigate additional orphan disease opportunities in due course.”. Disease Highlights. About Radius.

Disease 52

Disease FDA Approval Clinical Trials Trials 52

The Pharma Data

SEPTEMBER 28, 2021

After manufacturers analyze their clinical test data, they’re going to compile the knowledge and should request an emergency use authorization (EUA) or submit for approval a biologics license application (BLA), as appropriate, for this young population to the FDA. we’ve to let the science and data guide us.

Vaccine 52

Vaccine FDA Science Clinical Trials 52

The Pharma Data

JANUARY 18, 2021

Potential first-in-class disease-modifying biologic in late-stage clinical studies. Experienced executive development team from Gilead Sciences. Therefore, atacicept may be uniquely positioned to be disease-modifying for these patients with no current treatment options.”

Disease 40

Disease Science Clinical Development Treatment 40

LifeSciVC

JANUARY 16, 2024

recent announcements from Merck and Sanofi for obesity and broader metabolic disease). Rise of the best-in-class biologics plays: Are you looking to in-license or invest in “de-risked” biology that is already in the clinic? Join the club. Additional trials (e.g.,

Small Molecule 143

Small Molecule Trials Therapies Disease 143

Molecule Blog

JANUARY 9, 2023

IP-NFTs and Decentralized, Autonomous Science Today, most science is conducted at centralized institutions with a high barrier to entry and a reliance on imprecise human labor. Research is built on data (and sometimes code) that routinely isn’t shared, affecting our ability to replicate science.

Research 52

Research Licensing Licensing Science 52

The Pharma Data

MAY 5, 2022

Five out of ten patients who receive allogeneic stem cell transplants experience the serious and sometimes fatal symptoms of graft-versus-host disease,” says Marie-France Tschudin, Novartis President of Innovative Medicines International and Chief Commercial Officer. BAT, among steroid-refractory/dependent chronic GvHD patients 2,3.

Treatment 52

Treatment Disease Therapies Clinical Trials 52

The Pharma Data

JANUARY 18, 2021

The funds will be used to advance its nose-on-chip platform to detect the characteristic smell linked to Parkinson’s disease (PD). Yesse Technologies scientists recently validated the presence of a distinctive smell, arising from an oily skin secretion called sebum, in patients diagnosed with Parkinson’s disease.

Disease 40

Disease Molecular Biology Licensing Licensing 40

The Pharma Data

MARCH 5, 2021

Biogen (Nasdaq: BIIB) today announced it will host webcasts of its pre-recorded presentations and live discussions related to its Alzheimer’s disease investigational therapy, aducanumab, at the upcoming AD/PDTM 2021 Virtual Conference. Senior Medical Director, Global Safety and Regulatory Sciences at Biogen.

Licensing 52

Licensing Licensing Biosimilars Disease 52

Drug Target Review

FEBRUARY 28, 2024

from 2003 to 2006, covering the biotechnology and life-science tools sectors. Mr. Ho was an inductee into the McMaster University Alumni Gallery in 2020 and currently serves as a member of their Dean’s Advisory Board for the Faculty of Science. Human γδ TCR repertoires in health and disease. Science 294(5542):605-609 (2001).

Therapies 105

Therapies Engineering Molecular Biology Science 105

The Pharma Data

JANUARY 12, 2021

13, 2021 (GLOBE NEWSWIRE) — Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, announces the appointment of Dr Neil Graham MBBS, MD, MPH as Chief Medical Officer. Graham earned an M.D.,

Science 52

Science Clinical Development Disease Production 52